Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors

Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors

Considering the risk of reactivation of latent tuberculosis infection (LTBI), not only before starting tumor necrosis factor inhibitors but also before non-TNF inhibitor therapy, LTBI screening is routinely recommended for patients with inflammatory bowel disease (IBD). However, data on the positive...

Full description

Bibliographic Details
Main Authors: Kyuwon Kim, Kyung-Wook Jo, Tae Sun Shim, Jin Hwa Park, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Medicine
Subjects:
inflammatory bowel disease
latent tuberculosis infection
interferon-gamma release assay
vedolizumab
ustekinumab
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.670242/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.670242/full

Similar Items